Climate change and resilience CSL recognises that climate change can affect all aspects of businesses and communities. Climate change hazards can have a direct effect on human health and further stress healthcare infrastructure, including the network of global manufacturing facilities and warehouses used by CSL in the production of life‑saving medicines and therapies. Given the evolving sustainability and climate-related standards, including the introduction of the mandatory Australian Sustainability Reporting Standard (ASRS), CSL has been working on updating the Company’s climate-related risks and opportunities assessment and will share its results, as part of the FY2026 reporting period. CSL’s last enterprise-wide climate risk and opportunity assessment was completed in 2022, using the latest IPCC Sixth Assessment Report (IPCC AR6) across CSL’s most critical infrastructure: manufacturing facilities and warehouses. The assessment looked at three scenarios and focused on a near‑term time horizon of 2030, in line with CSL’s 2030 Strategy. This was extended in FY2024 to include CSL Vifor’s St Gallen site in Switzerland. Any identified moderate or significant site‑based physical risks are integrated into existing operational risk management practices in accordance with the Enterprise Risk Management Framework, so facilities can monitor and manage risks as applicable to their location and operations. Transitional risks are managed by CSL at an enterprise level, as these risks generally span the network of facilities directly owned by CSL. On an annual basis CSL assesses the impact of climate risk on its financial reporting. For the year ended 30 June 2025, CSL has assessed the impact of climate risk on its financial reporting. No material accounting impacts or changes to judgements or other required disclosures have resulted from the assessment. While the assessment did not have a material impact for the year ended 30 June 2025, this may change in future periods as CSL regularly updates its assessment of the impact of the lower carbon economy. The impact assessment principally focuses on key judgement areas, being the valuation and useful lives of intangible and tangible assets, and the identification and valuation of provisions as well as contingent liabilities. Healthier Environment CSL’s Broadmeadows facility – Project Aurora Announced as the Winner of the 2025 ISPE Facility of the Year Award for Pharma 4.0 CSL Behring has been announced as the winner of the 2025 Facility of the Year Award (FOYA) by the International Society for Pharmaceutical Engineering (ISPE) in the Pharma 4.0 category for its groundbreaking Project Aurora. Project Aurora, specifically Facility F, is CSL Behring’s state-of-the-art Plasma Fractionation Facility in Broadmeadows. As the largest facility of its kind within the CSL network and globally, it significantly enhances its plasma processing capacity, increasing it ninefold to over 10 million plasma equivalent litres per year. Facility F produces intermediates for immunoglobulin, albumin, and haemophilia products, effectively addressing the growing global demand for plasma-based therapies. Projects like Aurora at the Broadmeadows site enable CSL to meet patients’ needs with greater flexibility and efficiency. This initiative enhances CSL’s plasma processing capabilities and sets a new standard for future projects across CSL’s global manufacturing network. This recognition underscores CSL’s commitment to innovation and transformation in pharmaceutical manufacturing. CSL is honoured to be recognised by ISPE (International Society for Pharmaceutical Engineering) and will continue to push the boundaries of pharmaceutical manufacturing by integrating advanced technologies and sustainable practices for the benefit of patients worldwide. Facility F represents a significant advancement in pharmaceutical manufacturing, embodying the principles of Pharma 4.0. This state-of-the-art facility leverages cutting-edge technologies and innovative design to enhance production efficiency and flexibility. The modular design of Facility F allows for continuous production operations and staged implementation and maintenance, ensuring that the facility can adapt to changing demands and technological advancements. “Our modular design approach, advanced automation, and digital twin technology, combined with our commitment to environmental sustainability, have transformed our operations and expanded patient access to lifesaving plasma therapies globally. This facility builds on our proud Australian heritage and represents a bright future for our Broadmeadows site and biopharma manufacturing in Australia.” Andrew Hodder, Site Head at the Broadmeadows site. Project Aurora’s technologies align with Pharma 4.0’s focus on digitalisation and smart manufacturing, helping CSL Behring maintain a competitive edge and strengthen local and global supply chains for reliable access to critical treatments. 38 Healthier World
RkJQdWJsaXNoZXIy MjE2NDg3